Cargando…
凡德他尼治疗5例晚期复治肺腺癌患者的临床观察及相关文献回顾
BACKGROUND AND OBJECTIVE: Vandetanib is a once-daily oral multi-target inhibitor of vascular endothelial growth factor receptor, epidermal growth factor receptor, and rearranged during transfection (RET) tyrosine kinases. The current study aimed to evaluate the effect and safety of vandetanib admini...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000258/ https://www.ncbi.nlm.nih.gov/pubmed/22336242 http://dx.doi.org/10.3779/j.issn.1009-3419.2012.02.11 |